Italia markets close in 31 minutes

Takeda Pharmaceutical Company Limited (0A87.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
15,89+0,16 (+1,02%)
Al 02:48PM GMT. Mercato aperto.
Schermo intero
Chiusura precedente15,73
Aperto15,89
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno15,89 - 15,89
Intervallo di 52 settimane15,89 - 15,89
Volume2
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)0,73
Rapporto PE (ttm)0,30
EPS (ttm)0,54
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A17,61
  • GlobeNewswire

    HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China

    — HUTCHMED to receive US$400 million upfront on deal closing and up to US$730 million in potential future milestone payments, totaling up to US$1.13 billion, plus royalties on net sales — — Marketing authorization submissions in the U.S., Europe and Japan planned to complete in 2023 — — Partnership approach aligned with HUTCHMED’s path to profitability and strategy to bring its innovative medicines to patients worldwide — — HUTCHMED to host a conference call and webcast at 8:30 a.m. EST (1:30 p.

  • GlobeNewswire

    Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma

    NEW YORK and PETAH TIKVA, Israel, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer and Takeda Israel, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502/NSY:TAK) ("Takeda"), announced today that the Israeli Ministry of Health has approved DANYELZA in I

  • GlobeNewswire

    ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox

    Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience WINSTON-SALEM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (“CKD”), today announce